
Personalised medicine to relieve the health service
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
New connections were made between the incubators in Gothenburg and Oslo.
Jan 30, 2023
Sofia Linden
GU ventures, an incubator that supports projects and companies spawned by the University of Gothenburg, visited Oslo Cancer Cluster on 25-26 January 2023. Anders Waas, Business Development Advisor for GU Ventures, was accompanied by several cancer companies from the Gothenburg milieu, including Sortina Pharma (Sara Rhost and Göran Landberg, Iscaff Pharma (Per Setterberg), Simsen diagnostics (Gustav Johansson) and Oncorena (Börje Haraldsson and Pål Falck).
The OCC Incubator team, consisting of Ketil Widerberg, CEO, Janne Nestvold, COO, and Thomas Andersson, Business Development Advisor, facilitated meetings with several companies from Oslo Cancer Cluster.
GU Ventures also participated at Cancer Crosslinks, an annual educational meeting which gathers prominent experts in oncology, providing a forum for networking and interaction.
Anders Waas commented: “We were very impressed by the research, the start-up companies and the activities at Oslo Cancer Cluster and strive to build a closer collaboration, which can benefit the development of cancer research and growth of cancer companies in the Oslo – Gothenburg region.”
Thomas Andersson commented: “This was a great experience for Oslo Cancer Cluster Incubator. We were very impressed by the quality of the companies from GU Ventures and look forward to collaborating more closely.”
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
Geir Hetland, Chief Financial Officer of Thermo Fisher Scientific, is the latest addition to the board of Oslo Cancer Cluster.